MedWatch

Almirall acquires rights to new psoriasis drug in Europe

Almirall has entered a commercialization agreement with Danish MC2 Therapeutics, meaning the Spanish dermatology company will take on European sales of MC2's Wynzora cream for treating psoriasis.

MC2 Therapeutics has sold off the exclusive rights to selling the firm's new cream treating plaque psoriasis in Europe.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs